• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高剂量(80Gy)强度调制放疗联合每日图像引导作为局限性前列腺癌的主要治疗手段。

High-dose (80 Gy) intensity-modulated radiation therapy with daily image-guidance as primary treatment for localized prostate cancer.

机构信息

Department of Radiation Oncology with Division of Medical Radiation Physics, Inselspital, University Hospital, and University of Bern, Bern, Switzerland.

出版信息

Strahlenther Onkol. 2010 Dec;186(12):687-92. doi: 10.1007/s00066-010-2180-8. Epub 2010 Nov 30.

DOI:10.1007/s00066-010-2180-8
PMID:21136028
Abstract

PURPOSE

to report acute and late toxicity in prostate cancer patients treated by high-dose intensity-modulated radiation therapy (IMRT) with daily image-guidance.

PATIENTS AND METHODS

from 06/2004-03/2008, 102 men were treated with 80 Gy IMRT with daily image-guidance. The risk groups were as follows: low, intermediate, and high risk in 21%, 27%, and 52% of patients, respectively. Hormone therapy was given to 65% of patients. Toxicity was scored according to the CTC scale version 3.0.

RESULTS

median age was 69 years and median follow-up was 39 months (range, 16-61 months). Acute and late grade 2 gastrointestinal (GI) toxicity occurred in 2% and 5% of patients, respectively, while acute and late grade 3 GI toxicity was absent. Grade 2 and 3 pretreatment genitourinary (GU) morbidity (PGUM) were 15% and 2%, respectively. Acute grade 2 and 3 GU toxicity were 43% and 5% and late grade 2 and 3 GU toxicity were 21% and 1%, respectively. After multiple Cox regression analysis, PGUM was an independent predictor of decreased late ≥ grade 2 GU toxicity-free survival (hazard ratio = 9.4 (95% confidence interval: 4.1, 22.0), p < 0.001). At the end of follow-up, the incidence of late grade 2 and 3 GU toxicity decreased to 7% and 1%, respectively.

CONCLUSION

GI toxicity rates after IMRT with daily image-guidance were excellent. GU toxicity rates were acceptable and strongly related to PGUM.

摘要

目的

报告采用每日图像引导高强度调强放疗(IMRT)治疗前列腺癌患者的急性和晚期毒性。

方法

2004 年 6 月至 2008 年 3 月,102 例患者接受 80Gy IMRT 联合每日图像引导治疗。风险组分别为:低危、中危和高危患者占 21%、27%和 52%。65%的患者接受了激素治疗。毒性根据 CTC 量表 3.0 进行评分。

结果

中位年龄为 69 岁,中位随访时间为 39 个月(16-61 个月)。急性和晚期 2 级胃肠道(GI)毒性分别为 2%和 5%,而无 3 级 GI 毒性。预处理泌尿生殖系统(GU)发病率 2 级和 3 级分别为 15%和 2%。急性 2 级和 3 级 GU 毒性分别为 43%和 5%,晚期 2 级和 3 级 GU 毒性分别为 21%和 1%。经多因素 Cox 回归分析,PGUM 是晚期≥2 级 GU 毒性无复发生存率降低的独立预测因素(危险比=9.4(95%置信区间:4.1,22.0),p<0.001)。随访结束时,晚期 2 级和 3 级 GU 毒性的发生率分别降至 7%和 1%。

结论

每日图像引导 IMRT 后 GI 毒性发生率极佳。GU 毒性发生率可接受,且与 PGUM 密切相关。

相似文献

1
High-dose (80 Gy) intensity-modulated radiation therapy with daily image-guidance as primary treatment for localized prostate cancer.高剂量(80Gy)强度调制放疗联合每日图像引导作为局限性前列腺癌的主要治疗手段。
Strahlenther Onkol. 2010 Dec;186(12):687-92. doi: 10.1007/s00066-010-2180-8. Epub 2010 Nov 30.
2
Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.局限性前列腺癌调强放疗后的晚期毒性:探索剂量-体积直方图参数以限制泌尿生殖系统和胃肠道毒性。
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):235-41. doi: 10.1016/j.ijrobp.2010.09.058. Epub 2010 Dec 14.
3
Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking.采用剂量递增调强放射治疗和器官追踪治疗的前列腺癌患者的急性和晚期毒性反应
Radiat Oncol. 2008 Oct 20;3:35. doi: 10.1186/1748-717X-3-35.
4
Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus.前列腺癌外照射治疗后的毒性:糖尿病男性患者迟发性发病分析。
Urology. 2013 Jun;81(6):1196-201. doi: 10.1016/j.urology.2013.01.047. Epub 2013 Mar 26.
5
Toxicity analysis of postoperative image-guided intensity-modulated radiotherapy for prostate cancer.术后图像引导强度调制放疗治疗前列腺癌的毒性分析。
Int J Radiat Oncol Biol Phys. 2010 Oct 1;78(2):435-41. doi: 10.1016/j.ijrobp.2009.08.023. Epub 2009 Nov 24.
6
High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patients.使用基于每日基准标记的位置验证进行前列腺癌的高剂量调强放疗:331例患者的急性和晚期毒性反应
Radiat Oncol. 2008 May 21;3:15. doi: 10.1186/1748-717X-3-15.
7
Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes.局部前列腺癌的超高剂量(86.4 Gy)调强放射治疗:毒性反应及生化指标结果
Int J Radiat Oncol Biol Phys. 2008 Jun 1;71(2):330-7. doi: 10.1016/j.ijrobp.2007.10.004. Epub 2007 Dec 31.
8
Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.主成分分析在预测接受低分割强度调制放射治疗的前列腺癌患者毒性中的作用。
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e415-21. doi: 10.1016/j.ijrobp.2011.01.024. Epub 2011 Apr 7.
9
Toxicity after intensity-modulated, image-guided radiotherapy for prostate cancer.调强适形、图像引导放疗治疗前列腺癌的毒性反应。
Strahlenther Onkol. 2010 Oct;186(10):535-43. doi: 10.1007/s00066-010-2144-z. Epub 2010 Sep 30.
10
A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer.一项关于前列腺癌质子治疗和调强放射治疗后毒性结果的病例对照研究。
Cancer. 2015 Apr 1;121(7):1118-27. doi: 10.1002/cncr.29148. Epub 2014 Nov 25.

引用本文的文献

1
Towards Personalized Radiotherapy in Pelvic Cancer: Patient-Related Risk Factors for Late Radiation Toxicity.迈向盆腔癌的个性化放疗:晚期放射毒性的患者相关风险因素
Curr Oncol. 2025 Jan 17;32(1):47. doi: 10.3390/curroncol32010047.
2
Dosimetric implications of inter- and intrafractional prostate positioning errors during tomotherapy : Comparison of gold marker-based registrations with native MVCT.断层放疗期间前列腺分次间和分次内定位误差的剂量学影响:基于金标注册与原始MVCT的比较
Strahlenther Onkol. 2017 Sep;193(9):700-706. doi: 10.1007/s00066-017-1141-x. Epub 2017 May 2.
3
Radical prostatectomy versus external beam radiotherapy for localized prostate cancer: Comparison of treatment outcomes.

本文引用的文献

1
Dose escalation in prostate radiotherapy up to 82 Gy using simultaneous integrated boost: direct comparison of acute and late toxicity with 3D-CRT 74 Gy and IMRT 78 Gy.前列腺放射治疗中剂量递增至 82Gy 采用同步整合增敏:与 3D-CRT 74Gy 和 IMRT 78Gy 的急性和晚期毒性的直接比较。
Strahlenther Onkol. 2010 Apr;186(4):197-202. doi: 10.1007/s00066-010-2065-x. Epub 2010 Mar 26.
2
Moderate dose escalation in three-dimensional conformal localized prostate cancer radiotherapy: single-institutional experience in 398 patients comparing 66 Gy versus 70 Gy versus 74 Gy.三维适形局部前列腺癌放疗中适度剂量递增:398例患者的单机构经验,比较66 Gy、70 Gy和74 Gy。
Strahlenther Onkol. 2009 Jul;185(7):438-45. doi: 10.1007/s00066-2009-2033-5. Epub 2009 Aug 28.
3
根治性前列腺切除术与局部前列腺癌的外照射放疗:治疗结果比较
Strahlenther Onkol. 2015 Apr;191(4):321-9. doi: 10.1007/s00066-014-0765-3. Epub 2014 Oct 23.
4
Feasibility and radiation induced toxicity regarding the first application of transperineal implementation of biocompatible balloon for high dose radiotherapy in patients with prostate carcinoma.经会阴入路实施生物相容性球囊在前列腺癌患者高剂量放疗中的可行性和放射诱导毒性的初步研究。
Radiat Oncol. 2013 Apr 8;8:82. doi: 10.1186/1748-717X-8-82.
5
Impact of the adaptor protein GIPC1/Synectin on radioresistance and survival after irradiation of prostate cancer.衔接蛋白 GIPC1/Synectin 对前列腺癌放射抵抗和照射后生存的影响。
Strahlenther Onkol. 2012 Dec;188(12):1125-32. doi: 10.1007/s00066-012-0228-7. Epub 2012 Nov 7.
6
Assessment of accuracy and efficiency of atlas-based autosegmentation for prostate radiotherapy in a variety of clinical conditions.评估基于图谱的自动分割在各种临床情况下前列腺放射治疗的准确性和效率。
Strahlenther Onkol. 2012 Sep;188(9):807-15. doi: 10.1007/s00066-012-0117-0. Epub 2012 Jun 7.
7
Comparison of preoperative short-course radiotherapy and long-course radiochemotherapy for locally advanced rectal cancer.术前短程放疗与长程放化疗治疗局部进展期直肠癌的比较。
Strahlenther Onkol. 2012 Jul;188(7):551-7. doi: 10.1007/s00066-012-0131-2. Epub 2012 May 27.
8
Dose-escalated simultaneous integrated-boost treatment of prostate cancer patients via helical tomotherapy.螺旋断层放疗对前列腺癌患者进行调强同步推量治疗。
Strahlenther Onkol. 2012 May;188(5):410-6. doi: 10.1007/s00066-012-0081-8. Epub 2012 Feb 26.
9
Comparison of seed brachytherapy or external beam radiotherapy (70 Gy or 74 Gy) in 919 low-risk prostate cancer patients.919 例低危前列腺癌患者种子近距离放疗或外照射放疗(70Gy 或 74Gy)的比较。
Strahlenther Onkol. 2012 Apr;188(4):305-10. doi: 10.1007/s00066-012-0078-3. Epub 2012 Feb 22.
10
Combination of dose escalation with technological advances (intensity-modulated and image-guided radiotherapy) is not associated with increased morbidity for patients with prostate cancer.联合剂量递增与技术进步(调强放疗和图像引导放疗)并不会增加前列腺癌患者的发病率。
Strahlenther Onkol. 2011 Aug;187(8):479-84. doi: 10.1007/s00066-011-2249-z. Epub 2011 Jul 25.
Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991.EORTC 试验 22991 中中高危局限性前列腺癌根治性放疗的急性毒性。
Eur J Cancer. 2009 Nov;45(16):2825-34. doi: 10.1016/j.ejca.2009.07.009. Epub 2009 Aug 12.
4
IMRT of prostate cancer: a comparison of fluence optimization with sequential segmentation and direct step-and-shoot optimization.前列腺癌的调强放射治疗:射束流优化与序贯分割及直接步进式射野优化的比较
Strahlenther Onkol. 2009 Jun;185(6):379-83. doi: 10.1007/s00066-009-1950-7. Epub 2009 Jun 9.
5
Dosimetric comparison of image guidance by megavoltage computed tomography versus bone alignment for prostate cancer radiotherapy.兆伏级计算机断层扫描图像引导与骨骼对齐在前列腺癌放射治疗中的剂量学比较
Strahlenther Onkol. 2009 Apr;185(4):241-7. doi: 10.1007/s00066-009-1913-z. Epub 2009 Apr 16.
6
Urinary toxicity after high dose intensity modulated radiotherapy as primary therapy for prostate cancer.高剂量调强放疗作为前列腺癌主要治疗手段后的泌尿毒性
Radiother Oncol. 2009 Jul;92(1):42-7. doi: 10.1016/j.radonc.2009.03.013. Epub 2009 Apr 6.
7
Image-guided radiotherapy for prostate cancer. Implementation of ultrasound-based prostate localization for the analysis of inter- and intrafraction organ motion.前列腺癌的图像引导放射治疗。基于超声的前列腺定位在分次间和分次内器官运动分析中的应用。
Strahlenther Onkol. 2008 Dec;184(12):679-85. doi: 10.1007/s00066-008-1902-7. Epub 2008 Dec 24.
8
Intra-fractional uncertainties in image-guided intensity-modulated radiotherapy (IMRT) of prostate cancer.前列腺癌图像引导调强放疗(IMRT)中的分次内不确定性
Strahlenther Onkol. 2008 Dec;184(12):668-73. doi: 10.1007/s00066-008-1875-6. Epub 2008 Dec 24.
9
Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking.采用剂量递增调强放射治疗和器官追踪治疗的前列腺癌患者的急性和晚期毒性反应
Radiat Oncol. 2008 Oct 20;3:35. doi: 10.1186/1748-717X-3-35.
10
Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer.荷兰局部前列腺癌放疗多中心剂量递增试验的最新情况。
Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):980-8. doi: 10.1016/j.ijrobp.2008.02.073. Epub 2008 May 19.